Announcement of the Sumitomo Pharma Lonasen® Tablets (Blonanserin Tablets) Repackaging, Latuda® Tablets (Lurasidone Hydrochloride Tablets) Outer Packaging Project, and the Completion Date and Commissioning Date of Supporting Environmental Protection Facilities
2022-03-14
According to the Interim measures for inspection and acceptance of environmental protection of the completed constructions and other relevant regulations, the Sumitomo Pharma discloses information about the announcement on the completion date and commissioning start and end dates of supporting environmental protection facilities of repackaging Lonasen® (blonanserin tablets) tablets and outer packaging project of Latuda® (lurasidone hydrochloride tablets) tablets, informing the public who may be affected by the project construction. The company understands the attitude of the public, welcomes suggestions from the public regarding this project through the announcement, and addresses their concerns.
Project name: Sumitomo Pharma Lonasen® tablets (blonanserin tablets) repackaging and Latuda® tablets (lurasidone hydrochloride tablets) outer packaging project
Owner: Sumitomo Pharma
Address: 115 Qingqiu Street, Suzhou Industrial Park
Construction overview: The project investment is RMB5 million. The company's business scope: Development and production of drugs that have obtained patent rights or administrative protection in China, such as new anti-cancer drugs, new cardiovascular drugs, other medical drugs, anti-allergic drugs, new drugs and diagnostic kits recognized by China, sales of products manufactured by the company, consulting services for medical products, and related businesses. This construction involves Sumitomo Pharma Lonasen® tablet (blonanserin tablets) repackaging project and Latuda® tablet (lurasidone hydrochloride tablets) outer packaging project. Both are expansion projects. The construction scale is repackaging 1.2 million Lonasen® tablets (blonanserin tablets) and outer packaging 5 million Latuda® tablets (lurasidone hydrochloride tablets) per year based on the existing equipment, which does not involve the production of the drugs.
1. Sewage
No new employees are involved with this project, and therefore, there is no increase in the amount of domestic sewage. The existing domestic sewage is treated using the sewage treatment plant of the park from the municipal sewage network. No sewage is produced during the production procedure.
2. Exhaust gas
No exhaust gas is produced during the production procedure of this project.
3. Noise pollution and treatment measures
This project relies on the existing equipment and uses low-noise equipment. The main noise reduction measures are proper layout, sound insulation in the workshop, and installation of vibration damping mats.
4. Solid waste pollution and treatment measures
No new employees are involved with this project, and there is no new domestic waste; a small amount of waste packaging materials is produced during the operation period, which is collected by the manufacturer and sold for disposal, and no secondary pollution is generated.
Repackaging 1.2 million Lonasen® tablets (blonanserin tablets):
1. Completion date: January 2017
2. Commissioning date: February 2016
Outer packaging 5 million Latuda® tablets (lurasidone hydrochloride tablets):
1. Completion date: August 2018
2. Commissioning date: September 2018
Residents, organizations, and other members of the public who are concerned about this project or reside within the impact area of the project.
The public can send letters and emails to the designated address in the announcement to express their opinions and concerns regarding the project. Please provide detailed contact information while expressing your opinion and concern, and the construction unit will review the public's opinion and concern regarding the construction project and take remedial measures.
Contact: 计刚
Tel: 13862671071
E-mail: jig@sumitomo-pharma.com.cn
